XEOMEEN (XEOMIN®) 100u (Spanish)

XEOMEEN offers high precision, safety, and tolerability in injectable neurotoxin therapy. It is suitable for use in both aesthetic medicine and neurology when administered by trained professionals.

• 100 units of botulinum toxin type A per vial

• No complexing proteins, lowering immunogenic potential

• Approved for both aesthetic and neurological indications

• Onset of action: 2 to 4 days post-injection

• Peak efficacy: Achieved within 7 to 14 days

• Duration of effect: Up to 12–16 weeks

• Must be reconstituted before injection

XEOMEEN is indicated for multiple aesthetic and therapeutic uses. In cosmetic dermatology, it is primarily used to treat glabellar lines (frown lines). In therapeutic settings, it is approved for several neuromuscular disorders.

Aesthetic Indication:

• Moderate to severe glabellar lines in adults under 65 years

Therapeutic Indications:

• Blepharospasm (eyelid spasms)

• Cervical dystonia (neck muscle dysfunction)

• Upper limb spasticity in adults

• Chronic sialorrhea (excessive salivation)

Contraindications:

• Hypersensitivity to botulinum toxin type A or any excipients

• Presence of infection at the injection site

• Patients with neuromuscular disorders (e.g., myasthenia gravis)

Common Side Effects:

• Headache

• Eyelid ptosis (drooping)

• Dry eyes or dry mouth

• Local injection site pain, redness, or swelling

• Muscle weakness, especially near injection area

Rare but Serious Effects:

• Allergic reactions (rash, anaphylaxis)

• Swallowing or breathing difficulties, particularly in high doses or sensitive patients

XEOMEEN is a lyophilized powder presented in a clear glass vial for reconstitution. Its formulation contains only the active neurotoxin and essential stabilizers, with no additives or animal proteins.

Packaging:

• Supplied in single-use vial with 100 units of powder

• Must be reconstituted with 0.9% sodium chloride before injection

• Vials are sealed and clearly labeled

Ingredients per vial:

• 100 units of botulinum toxin type A

• Human albumin (1.0 mg)

• Sucrose (4.7 mg)

It does not contain complexing proteins, preservatives, or latex, making it suitable for patients with allergies or sensitivities.

XEOMEEN must be administered by a qualified medical professional using intramuscular or intraglandular injections, depending on the indication. Reconstitution and injection must be done under sterile conditions.

Preparation:

• Reconstitute with 2.5 mL of 0.9% sodium chloride

• Gently mix; do not shake vigorously

• Use within 24 hours of reconstitution

Typical Dosage:

• Glabellar lines: 20 units, divided into 5 injection points (4 units each)

• Blepharospasm: 1.25 to 2.5 units per injection site, tailored to muscle

• Cervical dystonia: 200 to 300 units per session depending on muscle size

• Sialorrhea: 100 units divided bilaterally across salivary glands

Storage:

• Unopened vials: 2–8°C (refrigerator)

• After reconstitution: store at 2–8°C and use within 24 hours

• Do not freeze; discard if frozen